Prab: CSV import

2025-03-07T01:48:36Z

CSV import

← Older revision		Revision as of 01:48, 7 March 2025
Line 1:		Line 1:
	== Management of Tuberculosis ==		== Management of Tuberculosis ==

	[[File:Tuberculosis-drugs-and-actions.jpg~~\|thumb\|right~~\|Diagram of tuberculosis drugs and their actions]]		[[File:Tuberculosis-drugs-and-actions.jpg\|Diagram of tuberculosis drugs and their actions\|thumb\|right]]

	The management of [[tuberculosis]] (TB) involves a combination of medical treatment, public health strategies, and supportive care. The primary goal is to cure the patient, prevent transmission, and reduce the incidence of drug-resistant TB.		The management of [[tuberculosis]] (TB) involves a combination of medical treatment, public health strategies, and supportive care. The primary goal is to cure the patient, prevent transmission, and reduce the incidence of drug-resistant TB. This article outlines the standard treatment regimens, the management of drug-resistant TB, and the role of public health interventions.

	==~~= Medical~~ Treatment ===		== Standard Treatment Regimens ==

	~~The cornerstone of TB management is the use of anti-tubercular drugs.~~ The standard treatment ~~regimen~~ for ~~drug-susceptible~~ TB involves a combination of ~~four~~ first-line drugs:		The standard treatment for active TB involves a combination of antibiotics over a period of at least six months. The most commonly used first-line anti-TB drugs are:

	* [[Isoniazid]]		* [[File:Isoniazid_skeletal.svg\|Structure of Isoniazid\|thumb\|left]] '''Isoniazid (INH)''': A bactericidal drug that inhibits the synthesis of mycolic acids, essential components of the mycobacterial cell wall.
	* [[Rifampicin]]
	* [[Pyrazinamide]]
	* [[Ethambutol]]

	~~==== First~~-~~line Drugs ====~~		* [[File:Rifampicin_structure.svg\|Structure of Rifampicin\|thumb\|right]] '''Rifampicin (RIF)''': A bactericidal antibiotic that inhibits RNA synthesis by binding to the beta subunit of DNA-dependent RNA polymerase.

	[[File:~~Isoniazid_skeletal~~.svg\|thumb\|left~~\|Structure of Isoniazid~~]]		* [[File:Ethambutol.svg\|Structure of Ethambutol\|thumb\|left]] '''Ethambutol (EMB)''': A bacteriostatic agent that inhibits the synthesis of the mycobacterial cell wall by blocking arabinosyl transferases.

	* '''~~Isoniazid~~''': A ~~bactericidal agent~~ that ~~inhibits the synthesis of mycolic acids~~, ~~essential components of the~~ mycobacterial cell ~~wall~~.		* [[File:Pyrazinamide.svg\|Structure of Pyrazinamide\|thumb\|right]] '''Pyrazinamide (PZA)''': A prodrug that is converted to its active form in acidic environments, disrupting mycobacterial cell membrane metabolism and transport functions.

	[[File:~~Rifampicin_structure~~.svg\|thumb\|~~right\|Structure of Rifampicin~~]]		* [[File:Streptomycin_structure.svg\|Structure of Streptomycin\|thumb\|left]] '''Streptomycin (SM)''': An aminoglycoside antibiotic that inhibits protein synthesis by binding to the 30S subunit of the bacterial ribosome.

	* '''Rifampicin''': A bactericidal antibiotic that inhibits bacterial RNA synthesis by ~~binding to the beta subunit~~ of ~~DNA-dependent RNA polymerase~~.		The initial phase of treatment typically lasts two months and includes all four drugs (INH, RIF, PZA, and EMB). This is followed by a continuation phase of four months with INH and RIF.

	~~[[File:Pyrazinamide.svg\|thumb\|left\|Structure~~ of ~~Pyrazinamide]]~~		== Management of Drug-Resistant TB ==

	* '''Pyrazinamide''': A prodrug that is ~~converted~~ to ~~the active form~~, ~~pyrazinoic acid, in acidic conditions, disrupting mycobacterial cell membrane metabolism~~ and ~~transport functions~~.		Drug-resistant TB, including multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB), poses significant challenges. MDR-TB is resistant to at least isoniazid and rifampicin, while XDR-TB is resistant to these drugs plus any fluoroquinolone and at least one of the second-line injectable drugs.

	~~[[File:Ethambutol~~.~~svg\|thumb\|right\|Structure of Ethambutol]]~~		Treatment of drug-resistant TB requires the use of second-line drugs, which are less effective, more toxic, and more expensive. The treatment duration is also longer, often extending to 18-24 months. Newer drugs such as bedaquiline and delamanid have been introduced to improve outcomes in drug-resistant TB cases.

	* '''Ethambutol''': Inhibits arabinosyl transferases involved in the polymerization of arabinogalactan, an essential component of the mycobacterial cell wall.		== Public Health Strategies ==

	~~==== Second-line Drugs ====~~		Public health strategies are crucial in the management of TB. These include:

	~~In cases of drug-resistant TB, second-line drugs are used~~. ~~These include:~~		* '''Directly Observed Therapy (DOT)''': Ensures adherence to treatment by having healthcare workers observe patients taking their medication.

	* ~~[[Streptomycin]]~~		* '''Contact Tracing and Screening''': Identifies and tests individuals who have been in contact with TB patients to prevent further spread.
	* [[Ciprofloxacin]]
	* [[Moxifloxacin]]
	* [[P-Aminosalicylic acid]]

	[[~~File:Streptomycin_structure.svg\|thumb\|left\|Structure of Streptomycin~~]]		* '''Vaccination''': The [[BCG vaccine]] is used in many countries to prevent severe forms of TB in children.

	* '''~~Streptomycin~~''': ~~An aminoglycoside antibiotic that inhibits protein synthesis by binding to~~ the ~~30S ribosomal subunit~~.		* '''Health Education''': Increases awareness about TB transmission, symptoms, and the importance of completing treatment.

	~~[[File:Ciprofloxazin.svg\|thumb\|right\|Structure of Ciprofloxacin]]~~		== Supportive Care ==

	* '''Ciprofloxacin''': A fluoroquinolone that inhibits bacterial DNA gyrase and topoisomerase IV, essential for ~~DNA replication.~~		Supportive care for TB patients includes nutritional support, management of comorbidities such as [[HIV/AIDS]], and psychological support to address the stigma associated with the disease.

	~~[[File:Moxifloxacin.svg\|thumb\|left\|Structure of Moxifloxacin]]~~

	* '''Moxifloxacin''': Another fluoroquinolone with a similar mechanism of action to ciprofloxacin, used in multidrug-resistant TB.

	~~[[File:P-Aminosalicylic_acid.svg\|thumb\|right\|Structure of P-Aminosalicylic acid]]~~

	* '''P-Aminosalicylic acid''': An antimetabolite that inhibits folic acid synthesis, interfering with mycobacterial growth.

	~~=== Treatment Regimens ===~~

	~~The standard treatment for drug-susceptible TB is a 6-month regimen:~~

	* '''Intensive phase''': 2 months of isoniazid, rifampicin, pyrazinamide, ~~and ethambutol.~~
	* '''Continuation phase''': 4 months of ~~isoniazid and rifampicin.~~

	~~For multidrug-resistant TB (MDR-TB), treatment is more complex and prolonged, often lasting 18-24 months, and involves second-line drugs.~~

	~~=== Monitoring and Support ===~~

	[[~~File:Tubi_-_1234,0186.jpg\|thumb\|left\|Chest X-ray of a patient with tuberculosis~~]]

	~~Monitoring of treatment involves regular follow-up visits, sputum smear microscopy~~, and ~~culture to assess response~~ to ~~therapy. Adherence to treatment is crucial to prevent relapse and~~ the ~~development of drug resistance. Directly Observed Therapy (DOT) is recommended to ensure compliance.~~

	~~=== Public Health Strategies ===~~

	~~Public health measures include contact tracing, vaccination~~ with the ~~[[BCG vaccine]], and health education to reduce transmission. Screening and preventive therapy for latent TB infection are also important components of TB control programs~~.

	== Related Pages ==		== Related Pages ==
Line 80:		Line 47:
	* [[Tuberculosis]]		* [[Tuberculosis]]
	* [[Multidrug-resistant tuberculosis]]		* [[Multidrug-resistant tuberculosis]]
	* [[~~Directly observed therapy~~]]		* [[Extensively drug-resistant tuberculosis]]
	* [[BCG vaccine]]		* [[BCG vaccine]]

	[[Category:Tuberculosis]]		[[Category:Tuberculosis]]
	[[Category:Infectious disease management]]		[[Category:Infectious disease management]]

Prab: CSV import

2025-03-04T21:50:16Z

CSV import

New page

== Management of Tuberculosis ==

[[File:Tuberculosis-drugs-and-actions.jpg|thumb|right|Diagram of tuberculosis drugs and their actions]]

The management of [[tuberculosis]] (TB) involves a combination of medical treatment, public health strategies, and supportive care. The primary goal is to cure the patient, prevent transmission, and reduce the incidence of drug-resistant TB.

=== Medical Treatment ===

The cornerstone of TB management is the use of anti-tubercular drugs. The standard treatment regimen for drug-susceptible TB involves a combination of four first-line drugs:

* [[Isoniazid]]
* [[Rifampicin]]
* [[Pyrazinamide]]
* [[Ethambutol]]

==== First-line Drugs ====

[[File:Isoniazid_skeletal.svg|thumb|left|Structure of Isoniazid]]

* '''Isoniazid''': A bactericidal agent that inhibits the synthesis of mycolic acids, essential components of the mycobacterial cell wall.

[[File:Rifampicin_structure.svg|thumb|right|Structure of Rifampicin]]

* '''Rifampicin''': A bactericidal antibiotic that inhibits bacterial RNA synthesis by binding to the beta subunit of DNA-dependent RNA polymerase.

[[File:Pyrazinamide.svg|thumb|left|Structure of Pyrazinamide]]

* '''Pyrazinamide''': A prodrug that is converted to the active form, pyrazinoic acid, in acidic conditions, disrupting mycobacterial cell membrane metabolism and transport functions.

[[File:Ethambutol.svg|thumb|right|Structure of Ethambutol]]

* '''Ethambutol''': Inhibits arabinosyl transferases involved in the polymerization of arabinogalactan, an essential component of the mycobacterial cell wall.

==== Second-line Drugs ====

In cases of drug-resistant TB, second-line drugs are used. These include:

* [[Streptomycin]]
* [[Ciprofloxacin]]
* [[Moxifloxacin]]
* [[P-Aminosalicylic acid]]

[[File:Streptomycin_structure.svg|thumb|left|Structure of Streptomycin]]

* '''Streptomycin''': An aminoglycoside antibiotic that inhibits protein synthesis by binding to the 30S ribosomal subunit.

[[File:Ciprofloxazin.svg|thumb|right|Structure of Ciprofloxacin]]

* '''Ciprofloxacin''': A fluoroquinolone that inhibits bacterial DNA gyrase and topoisomerase IV, essential for DNA replication.

[[File:Moxifloxacin.svg|thumb|left|Structure of Moxifloxacin]]

* '''Moxifloxacin''': Another fluoroquinolone with a similar mechanism of action to ciprofloxacin, used in multidrug-resistant TB.

[[File:P-Aminosalicylic_acid.svg|thumb|right|Structure of P-Aminosalicylic acid]]

* '''P-Aminosalicylic acid''': An antimetabolite that inhibits folic acid synthesis, interfering with mycobacterial growth.

=== Treatment Regimens ===

The standard treatment for drug-susceptible TB is a 6-month regimen:

* '''Intensive phase''': 2 months of isoniazid, rifampicin, pyrazinamide, and ethambutol.
* '''Continuation phase''': 4 months of isoniazid and rifampicin.

For multidrug-resistant TB (MDR-TB), treatment is more complex and prolonged, often lasting 18-24 months, and involves second-line drugs.

=== Monitoring and Support ===

[[File:Tubi_-_1234,0186.jpg|thumb|left|Chest X-ray of a patient with tuberculosis]]

Monitoring of treatment involves regular follow-up visits, sputum smear microscopy, and culture to assess response to therapy. Adherence to treatment is crucial to prevent relapse and the development of drug resistance. Directly Observed Therapy (DOT) is recommended to ensure compliance.

=== Public Health Strategies ===

Public health measures include contact tracing, vaccination with the [[BCG vaccine]], and health education to reduce transmission. Screening and preventive therapy for latent TB infection are also important components of TB control programs.

== Related Pages ==

* [[Tuberculosis]]
* [[Multidrug-resistant tuberculosis]]
* [[Directly observed therapy]]
* [[BCG vaccine]]

[[Category:Tuberculosis]]
[[Category:Infectious disease management]]

Management of tuberculosis - Revision history

Prab: CSV import

Prab: CSV import